Protective effect of sulforaphane on oxidative response in rats with sepsis-associated acute kidney injury

doi:10.3877/cma.j.issn.1674-6880.2021.03.003

Abstract

Abstract:

Objective

To explore the protective effect of sulforaphane on the oxidative response in rats with sepsis-associated acute kidney injury (SA-AKI).

Methods

Fifteen Sprague-Dawley rats were randomly allocated into a control group, a sepsis group and a treatment group, 5 rats in each group. Rats in the sepsis group and treatment group accepted cecal ligation and puncture (CLP) operation, while rats in the control group received celiotomy without ligation and puncture. Then rats in the treatment group received 5 mg / kg of sulforaphane for 15 min at 6 h after CLP, and rats in the other two groups received an equal amount of isotonic NaCl solution by intraperitoneal injection at the same time. At 24 h after CLP, blood samples from each group were collected to detect the levels of blood urea nitrogen and creatinine. Then, the rats were sacrificed and their renal tissue was collected to determine the levels of catalase (CAT), malondialdehyde and superoxide dismutase (SOD) by enzyme-linked immunosorbent assay. Meanwhile, the neutrophil gelatinase associated lipocalin (NGAL) messenger RNA (mRNA) expression in the renal tissue was detected by fluorescence real-time quantitative PCR.

Results

The levels of blood urea nitrogen (F = 922.714, P < 0.001), creatinine (F = 4 790.001, P < 0.001), CAT (F = 237.331, P < 0.001), malondialdehyde (F = 913.260, P < 0.001), SOD (F = 752.292, P < 0.001) and NGAL mRNA (F = 319.468, P < 0.001) all showed significant differences among the three groups. Further pairwise comparison revealed that compared with the control group, the levels of blood urea nitrogen [(5.98 ± 0.12), (14.93 ± 0.43), (11.99 ± 0.26) mmol / L], creatinine [(27.4 ± 0.9), (97.9 ± 1.0), (75.0 ± 1.2) μmol / L], malondialdehyde [(11.9 ± 0.4), (27.5 ± 0.7), (21.8 ± 0.4) nmol / mg] and NGAL mRNA in the sepsis group and treatment group increased obviously, which increased most in the sepsis group, and the levels of CAT [(21.64 ± 0.32), (17.06 ± 0.29), (19.96 ± 0.29) U / mg] and SOD [(71.6 ± 0.3), (54.2 ± 1.0), (59.7 ± 0.4) U / mg] decreased markedly, which decreased most in the sepsis group (all P < 0.05).

Conclusion

Sulforaphane can attenuate oxidative stress injury in rats with SA-AKI, and the mechanism is probably related to the inhibition of NGAL mRNA expression in kidney tissue.

Key words: Sepsis, Sulforphane, Acute kidney injury, Oxidative response, Rats

Luming Tang, Junnan Xu, Hainiao Lin, Ting Yang, Xiaodong Pan, Laifang Sun. Protective effect of sulforaphane on oxidative response in rats with sepsis-associated acute kidney injury[J]. Chinese Journal of Critical Care Medicine(Electronic Edition), 2021, 14(03): 187-191.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhwzzyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-6880.2021.03.003

https://zhwzzyxzz.cma-cmc.com.cn/EN/Y2021/V14/I03/187

Figures/Tables 3

References 26

1	Poston JT, Koyner JL Sepsis associated acute kidney injury[J]. BMJ, 2019 (364): k4891.
2	Gómez H, Kellum JA. Sepsis-induced acute kidney in-jury[J]. Curr Opin Crit Care, 2016, 22 (6): 546-553.
3	曾小娜，尹连红，许丽娜. 脓毒症急性肾损伤发病机制[J]. 生理科学进展，2020,51(2):122-126.
4	Dennis JM, Witting PK. Protective role for antioxidants in acute kidney disease[J]. Nutrients, 2017, 9 (7): 718.
5	Jiang X, Liu Y, Ma L, et al. Chemopreventive activity of sulforaphane[J]. Drug Des Devel Ther, 2018 (12): 2905-2913.
6	董春霞，杨莉. AKI的流行病学：AKI的发生率、患者死亡率、肾脏死亡率[J]. 中国血液净化，2017,16(1):8-10.
7	刘颖，孟超，赵谊，等. 自噬蛋白Beclin1及炎症因子表达在脓毒症急性肾损伤中的作用[J/CD]. 中华危重症医学杂志（电子版），2020,13(6):401-405.
8	吴炆晓，张爱华. 线粒体功能障碍与脓毒症急性肾损伤的研究进展[J]. 中华肾脏病杂志，2020,36(4):327-331.
9	Peerapornratana S, Manrique-Caballero CL, Gómez H, et al. Acute kidney injury from sepsis: current concepts, epidemiology, pathophysiology, prevention and treatment[J]. Kidney Int, 2019, 96 (5): 1083-1099.
10	葛勤敏，边帆，潘曙明. 脓毒症急性肾损伤研究进展[J]. 内科急危重症杂志，2016,22(6):460-463.
11	Podkowińska A, Formanowicz D. Chronic kidney dis-ease as oxidative stress- and inflammatory-mediated cardiovascular disease[J]. Antioxidants (Basel), 2020, 9 (8): 752.
12	Liguori I, Russo G, Curcio F, et al. Oxidative stress, aging, and diseases[J]. Clin Interv Aging, 2018 (13): 757-772.
13	Ho E, Karimi Galougahi K, Liu CC, et al. Biological markers of oxidative stress: applications to cardiovascular research and practice[J]. Redox Biol, 2013, 1 (1): 483-491.
14	Yatoo MI, Parray OR, Mir M, et al. Comparative e-valuation of different therapeutic protocols for contagious caprine pleuropneumonia in Himalayan Pashmina goats[J]. Trop Anim Health Prod, 2019, 51 (8): 2127-2137.
15	Basak P, Sadhukhan P, Sarkar P, et al. Perspectives of the Nrf-2 signaling pathway in cancer progression and therapy[J]. Toxicol Rep, 2017 (4): 306-318.
16	Liu P, Atkinson SJ, Akbareian SE, et al. Sulforaphane exerts anti-angiogenesis effects against hepatocellular carcinoma through inhibition of STAT3 / HIF-1α / VEGF signalling[J]. Sci Rep, 2017, 7 (1): 12651.
17	Ranaweera SS, Dissanayake CY, Natraj P, et al. Anti-inflammatory effect of sulforaphane on LPS-stimulated RAW 264.7 cells and ob / ob mice[J]. J Vet Sci, 2020, 21 (6): e91.
18	Pearson BL, Simon JM, McCoy ES, et al. Identification of chemicals that mimic transcriptional changes associated with autism, brain aging and neurodegeneration[J]. Nat Commun, 2016 (7): 11173.
19	Sun Y, Yang T, Mao L, et al. Sulforaphane protects against brain diseases: roles of cytoprotective enzymes[J]. Austin J Cerebrovasc Dis Stroke, 2017, 4 (1): 1054.
20	Nagata N, Xu L, Kohno S, et al. Glucoraphanin am-eliorates obesity and insulin resistance through adipose tissue browning and reduction of metabolic endotoxemia in mice[J]. Diabetes, 2017, 66 (5):1222-1236.
21	Brown RH, Reynolds C, Brooker A, et al. Sulfora-phane improves the bronchoprotective response in asthmatics through nrf2-mediated gene pathways[J]. Respir Res, 2015, 16 (1): 106.
22	Wu W, Peng G, Yang F, et al. Sulforaphane has a therapeutic effect in an atopic dermatitis murine model and activates the Nrf2 / HO-1 axis[J]. Mol Med Rep, 2019, 20 (2): 1761-1771.
23	Oh CJ, Kim JY, Min AK, et al. Sulforaphane atte-nuates hepatic fibrosis via NF-E2-related factor 2-mediated inhibition of transforming growth factor-β / Smad signaling[J]. Free Radic Biol Med, 2012, 52 (3): 671-682.
24	Bao B, Zhang MQ, Chen ZY, et al. Sulforaphane prevents PC12 cells from oxidative damage via the Nrf2 pathway[J]. Mol Med Rep, 2019, 19 (6): 4890-4896.
25	汤鲁明，王林霞，孙来芳，等. 萝卜硫素对脓毒症急性肺损伤大鼠氧化损伤及APE1表达的影响[J/CD]. 中华危重症医学杂志（电子版），2017,10(4):246-251.
26	徐建国，金献冠，李钰. 尿肾损伤分子1和中性粒细胞明胶酶相关脂质运载蛋白对脓毒症合并急性肾损伤患者早期连续性肾脏替代治疗的预测价值[J/CD]. 中华危重症医学杂志（电子版），2016,9(4):250-255.

组别	例数	血尿素氮（mmol / L）	血肌酐（μmol / L）
对照组	5	5.98 ± 0.12	27.4 ± 0.9
模型组	5	14.93 ± 0.43^a	97.9 ± 1.0^a
治疗组	5	11.99 ± 0.26^ab	75.0 ± 1.2^ab
F值		922.714	4 790.001
P值		< 0.001	< 0.001

组别	例数	血尿素氮（mmol / L）	血肌酐（μmol / L）
对照组	5	5.98 ± 0.12	27.4 ± 0.9
模型组	5	14.93 ± 0.43^a	97.9 ± 1.0^a
治疗组	5	11.99 ± 0.26^ab	75.0 ± 1.2^ab
F值		922.714	4 790.001
P值		< 0.001	< 0.001

组别	例数	CAT（U / mg）	丙二醛（nmol / mg）	SOD（U / mg）
对照组	5	21.64 ± 0.32	11.9 ± 0.4	71.6 ± 0.3
模型组	5	17.06 ± 0.29^a	27.5 ± 0.7^a	54.2 ± 1.0^a
治疗组	5	19.96 ± 0.29^ab	21.8 ± 0.4^ab	59.7 ± 0.4^ab
F值		237.331	913.260	752.292
P值		< 0.001	< 0.001	< 0.001

组别	例数	CAT（U / mg）	丙二醛（nmol / mg）	SOD（U / mg）
对照组	5	21.64 ± 0.32	11.9 ± 0.4	71.6 ± 0.3
模型组	5	17.06 ± 0.29^a	27.5 ± 0.7^a	54.2 ± 1.0^a
治疗组	5	19.96 ± 0.29^ab	21.8 ± 0.4^ab	59.7 ± 0.4^ab
F值		237.331	913.260	752.292
P值		< 0.001	< 0.001	< 0.001

[1]	Shengjin Han, Zhengwu Zhou, Yunlong Weng, Xin Huang. Effect of sodium bicarbonate Ringer's solution combined with continuous renal replacement therapy on inflammation level and renal function in trauma patients with acute kidney injury [J]. Chinese Journal of Critical Care Medicine(Electronic Edition), 2023, 16(05): 376-381.
[2]	Yuanyuan Han, Sabeiti Reziya, Zhijie Mao, Aierken Mufunayi, Chen Lu, Xiaohong Sang, Mulati Aerman, Li Zhang. Effect of combined blood purification on serum inflammatory cytokines levels and clinical prognosis in patients with sepsis [J]. Chinese Journal of Critical Care Medicine(Electronic Edition), 2023, 16(04): 272-278.
[3]	Jianbiao Meng, Geng Zhang, Yanna Jiao. Exploratory study on early intestinal microecological changes in patients with sepsis-induced myocardial dysfunction [J]. Chinese Journal of Critical Care Medicine(Electronic Edition), 2023, 16(04): 279-285.
[4]	Yu Chen, Fang Feng, Lu Zhang, Jian Liu. Bioinformatics analysis to screen key pathogenic genes in septic cardiomyopathy [J]. Chinese Journal of Critical Care Medicine(Electronic Edition), 2023, 16(04): 286-291.
[5]	Xiaoyan Zhang, Dongqiong Xiao, Hu Gao, Lin Chen, Fajuan Tang, Xihong Li. The protective effect and mechanism of overexpression of transcription factor 12 on the cerebral cortex of rats with sepsis-associated encephalopathy [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(05): 540-549.
[6]	Xu Wei, Ge Zhang, Jinlin Wu. Monitoring and treatment of neonatal sepsis-induced coagulopathy [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(04): 379-386.
[7]	Xiya Jin, Xiaosong Huang, Cheng Tan, Qin Jiang, Fang Hou, Yaoyue Li, Bing Xu, Honghui Jia, Wenying Liu. Antenatal treatment of tacrolimus on pulmonary vascular remodeling in rat with experimental pathological model of congenital diaphragmatic hernia [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(04): 428-436.
[8]	Xiaodan Wang, Yuan Wang, Xiangyu Cui, Xiaolei Ren. Analysis of pathogenic bacteria resistance of drug and high risk factors of death in urogenic sepsis after endoscopic surgery for upper urinary tract stones [J]. Chinese Journal of Endourology(Electronic Edition), 2023, 17(06): 611-615.
[9]	Xuecheng Wu, Yuanwei Li, Wuxiong Yuan, Jiansong Wang, Yongzhong Shi, Qiang Lu, Zhuo Li, Jia Chen, Zhe Liu, Yili Teng, Zhiyong Gao. Diagnostic value of inflammatory mediators profile combined with procalcitonin in urogenic sepsis [J]. Chinese Journal of Endourology(Electronic Edition), 2023, 17(05): 476-480.
[10]	Shangwen Dou, Huan Deng, Bangfeng Liu, Gaoyuanzhi Yue, Huacai Zhu, Yongda Liu. Role of preoperative urine culture re-examination in the prediction of infectious complications related to mini-percutaneous nephrolithotomy [J]. Chinese Journal of Endourology(Electronic Edition), 2023, 17(04): 361-366.
[11]	Qinglin Li, Renjie Song, Feihu Zhou. Establishment and exploration of a mouse model of severe exertional heat stroke-related acute kidney injury [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2023, 12(05): 265-270.
[12]	Jiafa Ren, Buyun Wu, Changying Xing, Huijuan Mao. Advances in the basic and clinical research on acute kidney injury in 2022 [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2023, 12(05): 276-281.
[13]	Jinpu Li, Xiangrong Rao. Antiviral drugs and acute kidney injury [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2023, 12(05): 287-290.
[14]	Cheng Yi, Wei Wei, Yuliang Zhao. The last piece of picture puzzle: conceptual evolution of acute kidney disease [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(08): 906-910.
[15]	Rui Tan, Jing Wang, Jiangquan Yu, Ruiqiang Zheng. Progress in understanding of role of high density lipoprotein, apolipoprotein A-I, and serum amyloid A in sepsis [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(06): 749-753.

Please choose a citation manager

Content to export